Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Number of US Patents per Small-Molecule Drug Has Tripled Since 1990, Delaying Generics

1 October 2026 · By · Wire by Fusion42

Published

1 October 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at cancertherapyadvisor.com →

◆ Verified

Fusion42 · 2 October 2026 · Fusion42 review

The number of US pharmaceutical patents per small-molecule drug more than tripled from 1990 to 2019, driven mostly by an increase in nonprimary patents which delay generic competition by extending exclusivity periods well beyond initial patent protection.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You must navigate a regulatory maze where extensive nonprimary patents now block generic entry much longer. This opens new strategic risks and opportunities in drug development and patent challenges.

◆ Coverage

1 source · 1 Oct 2026

◆ Related on Wire

◆ Topics

Biotechpharmaceutical-patentsdrug-exclusivitygeneric-drugspatent-litigation